Cell plasticity represents the ability of cells to be reprogrammed and to change their fate and
identity, enabling homeostasis restoration and tissue regeneration following damage. Cell …

The discoveries of EGFR mutations and ALK rearrangements as actionable oncogenic
drivers in non-small-cell lung cancer (NSCLC) has propelled a biomarker-directed treatment …

Small cell lung cancer (SCLC) is characterized by rapid growth and high metastatic capacity.
It has strong epidemiologic and biologic links to tobacco carcinogens. Although the majority …

Small-cell lung cancer (SCLC) represents about 15% of all lung cancers and is marked by
an exceptionally high proliferative rate, strong predilection for early metastasis and poor …

Anaplastic lymphoma kinase (ALK) is a potent oncogenic driver in lung cancer. ALK tyrosine
kinase inhibitors yield significant benefit in patients with ALK fusion-positive (ALK+) lung …

Tyrosine kinase inhibitors (TKIs) have dramatically changed the clinical prospects of patients
with non-small cell lung cancer harboring epidermal growth factor receptor (EGFR) …

Acquired drug resistance to anticancer targeted therapies remains an unsolved clinical
problem. Although many drivers of acquired drug resistance have been identified,,–, the …

Osimertinib is an irreversible, third-generation epidermal growth factor receptor (EGFR)
tyrosine kinase inhibitor that is highly selective for EGFR-activating mutations as well as the …

Abstract Epidermal Growth Factor Receptor (EGFR) enacts major roles in the maintenance
of epithelial tissues. However, when EGFR signaling is altered, it becomes the grand …

The impressive clinical activity of small-molecule receptor tyrosine kinase inhibitors for
oncogene-addicted subgroups of non-small-cell lung cancer (for example, those driven by …